The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study

BACKGROUND: ANCA associated vasculitides (AAV) often present with a chronic relapsing course. Relapse leads to increased immunosuppressive exposure and consequent toxicity. While two randomized controlled trials have shown rituximab (RTX) to be the most effective induction treatment in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Roccatello, Dario, Sciascia, Savino, Rossi, Daniela, Alpa, Mirella, Naretto, Carla, Radin, Massimo, Fenoglio, Roberta, Baldovino, Simone, Menegatti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581013/
https://www.ncbi.nlm.nih.gov/pubmed/28881714
http://dx.doi.org/10.18632/oncotarget.18120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581013/
https://www.ncbi.nlm.nih.gov/pubmed/28881714
http://dx.doi.org/10.18632/oncotarget.18120

Ejemplares similares